From vendor to tender: Thermo Fisher completes $7.2bn Patheon acquisition

By Dan Stanton contact

- Last updated on GMT

Image: iStock/xavigm
Image: iStock/xavigm

Related tags: Thermo fisher, Biotechnology

Thermo Fisher has entered the contract development and manufacturing (CDMO) space through the acquisition of Patheon.

The $7.2bn (€6bn) deal, first announced in May​, was completed this week and sees Thermo Fisher add small and large molecule contract manufacturing capacity, a network of production plants and 9,000 staff to its business.

“By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers,”​ Thermo Fisher’s CEO Marc Casper said in a press release yesterday.

Thermo Fisher is one a handful of major life science firm which supplies bioprocessing tech and tools to biomanufacturers. Its product offering, ranging from single-use bioreactors, to reagents, to chromatography equipment and consumables, has grown steadily through a series of acquisitions but this latest addition is an entirely new direction for Thermo Fisher.

Patheon – which reported $1.87bn in revenue last year – claims to have been involved in 17 out of 55 (30%) of all outsourced NDA approvals in 2016, and has a manufacturing network consisting of 30 plants.

By directly supplying bioprocessing technologies and capabilities, Patheon could increase its competitiveness over contract biomanufacturing rivals such as Catalent and Fujifilm

“With seamless access to our bioproduction capabilities, Patheon's biologics development and manufacturing capabilities will provide even greater benefit for customers,” ​Casper said back in May​. “Thermo Fisher's bioproduction business will also benefit from having an in-house world-class showcase for our technologies.”

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more